Healthcare Global Enterprises Ltd. · NSE:HCG
Healthcare Global Enterprises — Q4 FY21 Earnings Presentation
26 slides from Healthcare Global Enterprises's earnings presentation, Jun 17, 2021
Slide 1: Exchange filing cover letter: Investor Presentation
June 17, 2021 National Stock Exchange of India Limited, BSE Limited, Compliance Department, Compliance Department, Exchange Plaza, Bandra Kurla Complex, Phiroze Jeejeebhoy Towers, Bandra (East), Mumbai - 400051, Dalal Street, Mumbai - 400001, Maharashtra, India Maharashtra, India Dear Sir/Madam, Sub
Slide 2: HealthCare Global Enterprises Limited Investor Presentation Q4 & FY21
HealthCare Global Enterprises Limited Investor Presentation Q4 & FY21 www.hcgel.com © 2020 Healthcare Global Enterprises Limited 1
Slide 3: Disclaimer
Disclaimer THIS PRESENTATION AND ITS CONTENTS ARE CONFIDENTIAL AND ARE NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO OR FROM THE UNITED STATES OF AMERICA, CANADA, AUSTRALIA, JAPAN OR ANY JURISDICTION WHERE SUCH DISTRIBUTION IS UNLAWFUL. This pr
Slide 4: Leadership in specialty healthcare
Leadership in specialty healthcare www.hcgel.com © 2020 Healthcare Global Enterprises Limited 3
Slide 5: Overview Financial Highlights Appendix
Overview Financial Highlights Appendix www.hcgel.com © 2020 Healthcare Global Enterprises Limited 4
Slide 6: Overview of HCG (1/2)
Overview of HCG (1/2) Snapshot of the Business Comprehensive cancer diagnosis and Specialty healthcare provider with a focus treatment services (through radiation therapy, medical oncology and surgery) on cancer and fertility Largest1 provider of cancer care in India 226 comprehensive cancer
Slide 7: Overview of HCG (2/2)
Overview of HCG (2/2) Entry into fertility business Today India’s largest provider through the acquisition of 50.1% of cancer care¹ in BACC Healthcare Pvt. Ltd. Awarded Oncology Leader 2013 of the Year by Frost & Sullivan Milann ranked #1 nationally 2011 Entry into the clinical laboratory business t
Slide 8: HCG's Cancer Care Network
HCG’s Cancer Care Network Network of Existing and Under HCG Network Development Cancer Care centers Center of Excellence (CoE)1 Comprehensive Cancer center (22)2 Freestanding Diagnostic center (3)2 2,0361 28 17 Cancer centers Under Development (1) BEDS LI NEAR PET - CT ACCELERATORS SCANNE RS NCR Jai
Slide 9: Financial Highlights
Overview Financial Highlights Appendix www.hcgel.com © 2020 Healthcare Global Enterprises Limited 8
Slide 10: Financial Highlights: Q4-FY21
Financial Highlights: Q4-FY21 INR million except earnings per share Growth • Q4’21 Revenue grew by 10.2% y-o-y Period Ended Mar 31 Q4-FY21 Q4-FY20 (y-o-y) • HCG(1) centers: +11.7% Income from Operations 2,981 2,704 10.2% • Milann centers: -12.4% Other Income 44 17 • Q4’21 Operating EBITDA EBITDA(1 )
Slide 11: Financial Highlights: FY21
Financial Highlights: FY21 INR million except earnings per share Growth • FY’21 Revenue declined 7.5% y-o-y Period Ended Mar 31 FY21 FY20 (y-o-y) • HCG(1) centers: -5.5% • Milann centers: -36.7% Income from Operations 10,134 10,956 -7.5% Other Income 170 70 • FY’21 Operating EBITDA EBITDA(1 ) 1,435
Slide 12: Revenue Mix: FY-21
Revenue Mix: FY-21 Revenue: HCG Centers: INR 10,134 Mn INR 9,690 Mn Gujarat HCG (1) 29% Karnataka centers 34% (30%) 1 95% (35%)1 (94%) 1 Fertility (2) centers 5% North India Maharashtra (6%) 1 16% 1% (2%) 1 (14%) 1 A.P. East India Tamil Nadu 8% 9% 2% (8%) 1 (1) 22 comprehensive cancer centers, 3 mul
Slide 13: HCG Centers: Q4 & FY21 Revenues
HCG Centers: Q4 & FY21 Revenues INR million Growth Growth • Strong growth in revenue Period Ended Mar 31 Q4 -FY2 1 Q4 -FY2 0 (y-o-y) FY2 1 FY2 0 (y-o-y) continues across centers in Q4- FY21 Karnataka 1,038 934 11.1% 3,426 3,645 -6.0% Gujarat 757 723 4.6% 2,673 3,037 -12.0% • Ongole +50.3% y-o-y Maha
Slide 14: HCG Centers: FY21 Operating Metrics
HCG Centers: FY21 Operating Metrics No. of Centers Beds Avg. Occupancy Rate • Increase in Avg. Occupancy Rate in Q4- FY21 : FY21 : FY21 (y-o-y) FY21: 25 2,036 40.8% • 45.2% vs 41.1% (Consolidated) FY20: • 50.7% vs 45.6% (Existing centers) FY20: FY20: 2,071 42.9% • Increase in ARPOB in Q4-FY21 (y-o-y
Slide 15: HCG Centers: FY21 Regional Highlights
HCG Centers: FY21 Regional Highlights ARPOB Revenue Operating Centers Beds(4) AOR (INR/Day) (INR MN) EBITDA % Karnataka COE performance in Q4-FY21 Revenue growth 21.5% q-o-q & 6.6% y-o-y 7 615 44.9% 35.8K 3,426 19.5% ARPOB of INR 54k vs 57K (Q4-FY20) 23.8% operating EBITDA margin Revenue f
Slide 16: Milann: Implementing Strategic Initiatives
Milann: Implementing Strategic Initiatives Existing centers(1) New centers(2) Chandigarh Delhi Milann FY21 FY20 Growth New Registrations 3,578 5,481 -34.7% Bangalore (5 centers) IVF Cycles 1,450 2,195 -33.9% Revenue (INR Mn) 444 701 -36.7% M S Ramaiah Indiranagar Good recovery demonstrated in Q4-F
Slide 17: Capital Expenditure and Net Debt
Capital Expenditure and Net Debt Capital Expenditure Net Debt INR Million INR Million Q4-FY21 FY21 FY20 31-Mar-21 31-Dec-20 31-Mar-20 Net Debt HCG Centres Existing Centres 38 97 169 Bank Debt (1) 3,954 3,955 5,682 (2) Expansions 14 114 366 Vendor Finance 453 501 1,118 New Centres 48 140 717 Other De
Slide 18: Project Updates
Project Updates Additional 1 new HCG centers in FY2022 / 23 No new Milann center in FY2021 Bed Project Cost Start Location Capacity (INR mn) Date Location Start Date Jaipur, Rajasthan 50 410 Q2-FY19 Delhi Q1-FY17 Bhavnagar, Gujarat NA 150 Q2-FY19 Chandigarh Q3-FY17 Nashik Phase II, 92 623 Q2-FY19 Ma
Slide 19: Appendix
Overview Financial Highlights Appendix www.hcgel.com © 2020 Healthcare Global Enterprises Limited 18
Slide 20: Investment Thesis
Investment Thesis Strong Industry trends Largest provider of High quality care provided Strong management and growing oncology cancer care in India with at a competitive price team with successful cases backdrop a proven track record track-record www.hcgel.com © 2020 Healthcare Global Enterprises Li
Slide 21: Industry Trends and Backdrop
Industry Trends and Backdrop Cancer Incidences in India to Increase Incidence of Cancer Across Countries¹ 3.4 Cancer prevalence in India estimated to be 3.9mn in 2015 Estimated 1.6-2.2 Estimated 1.1mn new cancer cases reported in 2015 1.7 incidence of 1.1 0.9 cancer in 2015 (mns) Real incidenc
Slide 22: Industry Trends and Backdrop
Industry Trends and Backdrop Demand Supply Gap and Treatment Landscape Existing Demand Supply Gap in Diagnostics… …and Treatment Lack of adequate infrastructure and absence of mass A key requirement for successful radiation therapy is screening programs are key barriers to timely diagnosis avail
Slide 23: Largest Provider of Cancer Care in India
Largest Provider of Cancer Care in India A Proven Track Record¹ HCG’s market leading position, successful track record and strong reputation in India provides a significant advantage over its competitors Largest Cancer Care Provider… …With a Strong Track Record Largest provider of cancer care in I
Slide 24: High Quality Care
High Quality Care Provided at Competitive Price Ability to provide high quality care driven by a multidisciplinary and technology focused approach Approach to Providing High Quality Care… …Results in Successful Clinical Multidisciplinary approach to cancer care - specialist physicians from Outcome
Slide 25: Coverage by Harvard
Coverage by Harvard Unique and Successful Comparable outcomes Business Model at fraction of cost Survival Rate Cost Govindarajan et. al. .Harvard Business Review, November 2012, “Delivering World Class Health Care Affordably, Innovative hospitals in India are pointing the way”G www.hcgel.com © 2020
Slide 26: THANK YOU
THANK YOU For updates and specific queries, please visit www.hcgel.com or feel free to contact investors@hcgoncology.com © 2019 HealthCare Global Enterprises Limited., All Rights Reserved. HCG Logo is trademark of HealthCare Global Enterprises Limited In addition to Company data, data from market re
HealthCare Global Enterprises — Q4 FY21 Earnings Presentation on 6ix